Navigation Links
Abbott to Preview New CELL-DYN(R) Emerald(TM) Hematology Instrument
Date:7/28/2008

CELL-DYN Emerald Designed to Deliver Quick, Reliable Results for Small to

Mid-Sized Laboratories

WASHINGTON, July 28 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) will preview an upcoming addition to the CELL-DYN(R) family of hematology instruments, the Emerald(TM), at the American Association of Clinical Chemistry (AACC) Annual Meeting this week. The Emerald is designed to be a valuable tool for performing complete blood counts (CBCs) -- a test frequently ordered by doctors to assess a patient's overall health and to screen for a variety of disorders such as anemia and infection. The Emerald has the ability to complete CBC results in 60 seconds and report results in easy-to-read histograms representing white blood cells, red blood cells and platelets.

Expected to be available in the United States by the end of the year, subject to regulatory clearance, the Emerald will expand Abbott's hematology platform by offering a premium, robust low-volume solution for small to mid-sized clinical laboratories. Enhanced technology combined with intuitive software and onboard reagents enable the Emerald to offer reliable performance while promoting faster and simpler data entry.

As low to medium-volume hospital laboratories and clinics continue to seek greater efficiency under tight space limitations, the Emerald is expected to deliver reliable, productivity-enhancing performance in a small footprint.

The AACC Annual Meeting is a global meeting that attracts nearly 20,000 attendees from more than 100 countries. The Emerald is on display in Abbott's AACC exhibit booth (No. 1507).

About CELL-DYN

Abbott's CELL-DYN family of hematology instruments is well known for its efficiency and ability to provide fast access to patient results. Instruments range from larger analyzers that process a high number of patient samples to smaller instruments designed for medium and small-volume facilities. Besides supplying standard CBC results, some instruments have additional features to aid in the evaluation of more complex disease states or infections including cancer, HIV and a variety of anemias.

About Abbott's Diagnostics Businesses

Abbott is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices and clinics. With more than 65,000 customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, bedside testing, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnosis from an art to a science through the company's commitment to improving patient care and lowering costs. Abbott's history is filled with examples of first-of-a-kind diagnostic products and significant technological and research advancements.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Neil H. Greco Insurance Agency, ... to communities throughout the region, is launching a charity drive to raise awareness of ... far the deadliest killer in America, and is responsible for 1 in every 4 ...
(Date:1/17/2017)... Gatos, CA (PRWEB) , ... January 17, 2017 , ... ... announced the results of a double blind clinical study for its dental gel that ... a leading national brand of toothpaste containing triclosan. The study was conducted at the ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... from two offices in Tyler, has announced the latest beneficiary of their thriving ... Network, a nonprofit organization dedicated to fulfilling the dreams of terminally ill patients. ...
(Date:1/17/2017)... ... , ... Today, FloSports , a global leader in live digital sports ... of a long-term extension of their media partnership. The partnership, which began in 2013, ... sport’s premier events exclusively on FloWrestling.com as well as usage of the FloArena meet ...
(Date:1/16/2017)... Creek, MI (PRWEB) , ... January 17, 2017 , ... ... abuse located in Southwest Michigan, joined other volunteers and organizations in support of the ... hundreds of children and families dressed up in colorful costumes of all designs coming ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... ® Technologies, Inc. announces that the Journal ... of Vibration on Molar Distalization," a study that focused ... Bowman , this prospective, peer-reviewed clinical study concluded that ... speeds up molar distalization rates in the apex ... to move the upper molars into a normal, Class ...
(Date:1/17/2017)... Jan. 17, 2017 Following an initial ... praised the Food and Drug Administration,s (FDA,s) final ... Drug Products by Pharmacies and Outsourcing Facilities." In ... limitation on pre-packaging -- which would have put ... to long term care (LTC) pharmacies.  ...
(Date:1/17/2017)... DUBLIN , Jan 17, 2017 Research ... Ingredients/API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, ... CVD) - Global Forecast to 2021" report to their offering. ... The global ... by 2021 from USD 157.95 Billion in 2016, growing at a ...
Breaking Medicine Technology: